Cetuximab
Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan AIDS Malignancy Consortium | Phase 1/2 | B |
Everolimus Fox Chase Cancer Center | Phase 1 | CC |
7-hydroxystaurosporine National Cancer Institute (NCI) | Phase 1 | CC |
cc-5013 National Cancer Institute (NCI) | Phase 1 | CC |
Alvespimycin National Cancer Institute (NCI) | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Cetuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →